Stockscreener 앱 받기
7.03
1.44%
0.10
시장 영업 전:
7.07
0.04
+0.57%
전일 마감가:
$6.93
열려 있는:
$7.04
하루 거래량:
3.57M
Relative Volume:
0.80
시가총액:
$1.48B
수익:
$557.51M
순이익/손실:
$-35.71M
주가수익비율:
-39.06
EPS:
-0.18
순현금흐름:
$15.50M
1주 성능:
+1.88%
1개월 성능:
+1.44%
6개월 성능:
-31.95%
1년 성능:
-3.70%
1일 변동 폭
$6.89
$7.09
1주일 범위
$6.73
$7.205
52주 변동 폭
$6.00
$11.31
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
BCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
7.03 | 1.46B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-15 | 재개 | TD Cowen | Buy |
| 2025-10-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 개시 | Wedbush | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy |
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2020-09-29 | 재개 | JP Morgan | Overweight |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 재개 | Piper Jaffray | Overweight |
| 2018-08-08 | 재개 | JP Morgan | Overweight |
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral |
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 개시 | Barclays | Equal Weight |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | FBR Capital | Outperform |
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
Biotech Stocks Facing FDA Decision In December 2025 - RTTNews
Why BioCryst (BCRX) Might be Well Poised for a Surge - sharewise.com
BioCryst to Present at Morgan Stanley Global Healthcare Conference - AOL.com
Will BioCryst Pharmaceuticals Inc. stock return to pre crisis levelsMarket Sentiment Review & Free High Return Stock Watch Alerts - newser.com
Why BioCryst Pharmaceuticals Inc. stock could benefit from AI revolutionJuly 2025 Spike Watch & Technical Pattern Based Buy Signals - newser.com
BioCryst at Jefferies Conference: Strategic Growth and Acquisitions By Investing.com - Investing.com Canada
BCRX: ORLADEYO growth, Astria acquisition, and Nevenabart launch drive profitability and pipeline momentum - TradingView
Why retail investors pile into BioCryst Pharmaceuticals Inc. stock2025 Market Outlook & Daily Stock Momentum Reports - newser.com
Will BioCryst Pharmaceuticals Inc. stock attract ESG investors2025 Top Decliners & Safe Swing Trade Setups - newser.com
Can BioCryst Pharmaceuticals Inc. stock deliver consistent earnings growth2025 Valuation Update & AI Powered Market Trend Analysis - newser.com
Is BioCryst Pharmaceuticals Inc. stock ready for a breakoutGlobal Markets & Weekly Momentum Picks - newser.com
BioCryst Pharmaceuticals Inc.’s volatility index tracking explainedPortfolio Value Report & Real-Time Volume Analysis Alerts - newser.com
Astria Therapeutics Reports Q3 2025 Results and BioCryst Acquisition - TipRanks
Why Analysts Say the BioCryst Story Is Changing After Astria Therapeutics Acquisition - Yahoo Finance
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - MarketScreener
Is BioCryst Pharmaceuticals Inc. stock bottoming out2025 Analyst Calls & Daily Technical Forecast Reports - newser.com
Will BioCryst Pharmaceuticals Inc. stock maintain growth storyBull Run & Growth-Oriented Investment Plans - newser.com
Trading the Move, Not the Narrative: (BCRX) Edition - news.stocktradersdaily.com
Is BioCryst’s Surging ORLADEYO Sales and Astria Deal Reshaping the Investment Case for BCRX? - Sahm
BioCryst Pharmaceuticals, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - 富途牛牛
Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - simplywall.st
BioCryst’s ORLADEYO shows sustained attack reduction in pediatric HAE By Investing.com - Investing.com South Africa
BioCryst’s ORLADEYO shows sustained attack reduction in pediatric HAE - Investing.com
BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat) - GlobeNewswire
Is BioCryst Pharmaceuticals Inc. stock ready for breakoutEarnings Risk Summary & Weekly High Potential Alerts - Fundação Cultural do Pará
BioCryst Pharmaceuticals Shines in Q3 Earnings Call - MSN
Can BioCryst Pharmaceuticals Inc. stock outperform in 2025 bull market2025 Breakouts & Breakdowns & Weekly High Return Forecasts - Fundação Cultural do Pará
What technical models suggest about BioCryst Pharmaceuticals Inc.’s comebackPortfolio Profit Report & Real-Time Buy Zone Alerts - newser.com
When is the best time to exit BioCryst Pharmaceuticals Inc.2025 Major Catalysts & Pattern Based Trade Signal System - newser.com
Citizens Maintains BioCryst Pharmaceuticals (BCRX) Market Outperform Recommendation - Nasdaq
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.17%
0.67%
자본화:
|
볼륨(24시간):